Performance Nutrition's KidsPlex, Jr. ADD treatment claims draw FDA warning letter.
This article was originally published in The Tan Sheet
Executive Summary
PERFORMANCE NUTRITION KIDSPLEX, JR. ADD/ADHD CLAIMS DRAW WARNING LETTER from FDA to the Dallas-based nutritional supplements distributor. In the Dec. 4 letter, FDA takes aim at "objectionable" Performance Nutrition claims that make KidsPlex, Jr. an unapproved new drug. The claims include: "KidsPlex, Jr., because of its fortification with inhibitory amino acids, has the potential to help children with Attention Deficit Hyperactivity Disorder."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning